- 4-Week # shares sold: 2,296
- 12-Week # shares sold: 2.0 million
- 24-Week # shares sold: 2.2 million
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
Here are Tuesday's top research calls, including upgrades for Biogen and Caterpillar, and increased price targets for Apple and Micron.